TCRX vs. LXEO, OCGN, ADPT, ALEC, ALLO, VYGR, EDIT, TSHA, ABSI, and FATE
Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Lexeo Therapeutics (LXEO), Ocugen (OCGN), Adaptive Biotechnologies (ADPT), Alector (ALEC), Allogene Therapeutics (ALLO), Voyager Therapeutics (VYGR), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Absci (ABSI), and Fate Therapeutics (FATE). These companies are all part of the "medical" sector.
Lexeo Therapeutics (NASDAQ:LXEO) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.
TScan Therapeutics received 17 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 74.19% of users gave TScan Therapeutics an outperform vote.
Lexeo Therapeutics presently has a consensus price target of $20.80, suggesting a potential upside of 30.24%. TScan Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 40.19%. Given Lexeo Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Lexeo Therapeutics.
In the previous week, TScan Therapeutics had 4 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for TScan Therapeutics and 4 mentions for Lexeo Therapeutics. TScan Therapeutics' average media sentiment score of 0.94 beat Lexeo Therapeutics' score of 0.52 indicating that Lexeo Therapeutics is being referred to more favorably in the media.
Lexeo Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 2.8% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Lexeo Therapeutics has a net margin of 0.00% compared to Lexeo Therapeutics' net margin of -653.50%. Lexeo Therapeutics' return on equity of -61.13% beat TScan Therapeutics' return on equity.
Summary
Lexeo Therapeutics and TScan Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get TScan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TScan Therapeutics Competitors List
Related Companies and Tools
